CDK4 and prostate cancer: Formononetin can induce prostate cancer transformation through the ERK1/2 MAPK-Bax pathway [35], which can also inhibit the G1 cell cycle by inactivating Akt/cyclin D1/CDK4, making it exhibit inhibitory activity on human prostate cancer cells both in vivo and in vitro [36].